TD Cowen Maintains Standard BioTools(LAB.US) With Buy Rating, Maintains Target Price $2.5
TD Cowen Maintains Standard BioTools(LAB.US) With Buy Rating, Cuts Target Price to $2.5
TD Cowen Maintains Standard BioTools(LAB.US) With Buy Rating, Maintains Target Price $2.75
Standard BioTools (LAB) Receives a Buy From TD Cowen
TD Cowen Maintains Buy on Standard BioTools, Lowers Price Target to $2.75
TD Cowen Maintains Standard BioTools(LAB.US) With Buy Rating, Cuts Target Price to $2.75
Maintaining a Buy Rating for Standard BioTools: Overcoming Short-Term Challenges With Long-Term Growth Potential
Standard BioTools Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Standard BioTools (LAB)
Standard BioTools Analyst Ratings
KeyBanc Initiates Standard BioTools at Overweight With $4 Price Target, Sees 'Attractively Valued Way to Invest' in Life Sciences Technology
Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (CNC) and Standard BioTools (LAB)
Keybanc Initiates Coverage On Standard BioTools With Overweight Rating, Announces Price Target of $4
Standard BioTools Analyst Ratings
No Data
No Data